Traws Pharma, Inc.
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$1.21
FAIR PRICE
$1.78
MARGIN
$0.57
FPI RATING
Attractive valuation and high-quality fundamentals, but limited growth momentum and weak profitability margins.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$1.42
Fair price × 0.80
DISTANCE
17.7%
Price to entry level
At the current price of $1.21, TRAW trades 17.7% below the conservative entry level of $1.42. The stock is currently priced below the 20% margin of safety threshold, indicating a potential value opportunity based on the model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
Loading chart data...
COMING SOON
Get notified when TRAW's fair price changes
Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.
iOS and Android · Free tier available
KEY FACTS
CEO
Iain D. Dukes
COUNTRY
US
HEADQUARTERS
Newtown
SECTOR
Healthcare
EXCHANGE
NASDAQ
METHODOLOGY
How we calculate TRAW's fair price
Traws Pharma, Inc.'s fair price of $1.78 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $1.21, TRAW trades 47.1% below its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting TRAW's risk profile.
RELATIVE · 30%
Comparing TRAW's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for TRAW, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate TRAW's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for TRAW.
Explore on BuliosFAQ
What is the fair price of TRAW?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Traws Pharma, Inc. is $1.78. At the current market price of $1.21, TRAW trades 47.1% below its calculated fair value.
Is TRAW overvalued or undervalued?+
Traws Pharma, Inc. is currently undervalued based on our valuation model. The stock trades at $1.21, which is 47.1% below the fair price of $1.78. The P/E ratio of 1.5x is a key metric in the valuation.
What is the margin of safety for TRAW?+
With a 20% margin of safety applied to the fair price of $1.78, the conservative entry level for TRAW is $1.42. At the current market price of $1.21, the stock trades 17.7% below this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is TRAW's fair price updated?+
We update fair price calculations for TRAW daily after market close. The current fair price of $1.78 incorporates the latest market data and sector multiples.
What factors affect TRAW's fair price calculation?+
TRAW's fair price of $1.78 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight). Key metrics include P/E of 1.5x, ROE of 531.6%.
Is TRAW a good buy right now?+
At $1.21, TRAW trades 47.1% below our fair value estimate of $1.78. The stock is currently undervalued. ROE stands at 531.6% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.
Does TRAW pay dividends?+
TRAW does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.